MedImmune announced that it is expanding its intranasal vaccine research following news of successful preclinical studies against three respiratory viruses in children. The company said that results of a study published in the Journal of Virology suggested that the technology promoted protective immune responses against respiratory syncytial virus, human metapneumovirus, and parainfluenzavirus type 3. Preliminary studies have also shown that diseases caused by multiple respiratory viruses may be preventable with just one vaccine using intranasal technology.